Clinical trials: Eye Inflammation
Inflammation, Uveitis
Evaluation of Corneal Endothelial Cell Density in Subjects Who Have Had a Fluocinolone Acetonide Implant
Investigate the impact of the Fluocinolone Acetonide (FA) intravitreal implants
- Trial name
- NCT01060787
- Testing
- Fluocinolone Acetonide 0.59 mg, Fluocinolone Acetonide 2.1 mg
- Where
- United States
- Volunteers
- 98 people
- Sponsor
- Bausch & Lomb Incorporated
Corneal Endothelial Cell Loss, Ocular Pain
RTA 408 Ophthalmic Suspension for the Prevention of Corneal Endothelial Cell Loss Following Cataract Surgery - GUARD
This study assesses the efficacy and safety of two concentrations of omaveloxolone (RTA 408) ophthalmic suspension for the prevention of corneal endothelial cell loss following cataract surgery.
- Conditions
- Corneal Endothelial Cell Loss, Ocular Pain, Ocular Inflammation, Cataract Surgery
- Trial name
- NCT02128113
- Testing
- Vehicle Ophthalmic Solution, Omaveloxolone Ophthalmic Suspension 0.5%, Omaveloxolone Ophthalmic Suspension 1%
- Where
- 15 sites in United States
- Volunteers
- 307 people
- Sponsor
- Biogen
Cataract
Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
The objective of this study is to compare the efficacy and safety for the treatment of postoperative inflammation following ocular surgery for childhood cataract.
- Trial name
- NCT01475643
- Testing
- Loteprednol etabonate, Prednisolones acetate
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Bausch & Lomb Incorporated
Postoperative Ocular Inflammation, Postoperative Ocular Pain
A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery
This study is designed to evaluate the safety and efficacy of TRIESENCE® (triamcinolone acetonide injectable suspension) in patients undergoing ophthalmic procedures.
- Trial name
- NCT07832552
- Testing
- TRIESENCE (triamcinolone acetonide injectable suspension)
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Harrow Inc
Ocular Inflammation
Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients
This study will test the efficacy and safety of IBI-10090 in the treatment of ocular inflammation after cataract surgery.
- Trial name
- NCT01214174
- Testing
- IBI-10090
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- ICON Bioscience Inc
Cataract in Inflammatory Ocular Disorders
A Clinical Study to Assess the Efficacy and Safety of SED80 for Use in Cataract Surgery
Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of four groups of dexamethasone ophthalmic suspension or placebo eye drops to determine if the drops decrease…
- Trial name
- NCT04711213
- Testing
- Dexamethasone Dose 1, Dexamethasone Dose 2
- Where
- El Salvador
- Volunteers
- 60 people
- Sponsor
- iDrop, Inc.
Cataract, Inflammation
Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery
This clinical study is being conducted to identify the most effective drug concentration and dose frequency of BOL-303242-X (Mapracorat) ophthalmic suspension, for the treatment of inflammation following cataract surgery.
- Trial name
- NCT00905450
- Testing
- BOL-303242-X, Vehicle for BOL-303242-X
- Where
- United States
- Volunteers
- 415 people
- Sponsor
- Bausch & Lomb Incorporated
Inflammation Eye Pain, Postoperative Cataract
A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Opthalmic Suspension Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
This was a randomized, double-masked, vehicle-controlled, Phase 3 study evaluating the efficacy and safety of OCS-01 QD compared to vehicle in the treatment of inflammation and pain following cataract surgery.
- Trial name
- OPTIMIZE-2 (NCT06128369)
- Testing
- OCS-01, Vehicle
- Where
- 24 sites in United States
- Volunteers
- 117 people
- Sponsor
- Oculis
Cataract
Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
The purpose of this study is to compare the clinical outcomes, safety and efficacy in patients randomized to receive either ketorolac or nepafanac following cataract surgery.
- Trial name
- NCT00348582
- Testing
- Ketorolac, Nepafenac
- Where
- United States
- Sponsor
- Innovative Medical
Ocular Infections, Irritations and Inflammations
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation
The primary purpose of this study is to determine the efficacy and safety of KPI-121 ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- Hawaii-1 (NCT02163824)
- Testing
- KPI-121 0.25%, KPI-121 1.0%, Vehicle of KPI-121 0.25%
- Where
- 23 sites in United States
- Volunteers
- 380 people
- Sponsor
- Kala Pharmaceuticals, Inc.
Cataracts Infantile
Clobetasol Propionate Ophthalmic Nanoemulsion, 0.05% in the Treatment of Inflammation After Cataract Surgery in Pediatric Population
Multicenter, randomized, evaluator-blinded clinical trial compared to Prednisolone acetate, 1% in the treatment of inflammation and pain after cataract surgery in pediatric population.
- Trial name
- CLOSE-3 (NCT05724446)
- Testing
- Clobetasol Propionate, Prednisolone acetate ophthalmic suspension, 1%
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Salvat
Cataract
Difluprednate vs. a Prednisolone Acetate - Phenylephrine on Post-operative Inflammation Following Cataract Surgery.
This controlled, randomized, double blind, multicenter study will be carried out to demonstrate that the topical ophthalmic nanoemulsion of difluprednate 0.05% (Tolf®, Poen Laboratories), has a high anti-inflammatory efficacy…
- Trial name
- NCT04631315
- Testing
- Difluprednate Ophthalmic Emulsion 0.05%, Prednisolone Acetate 1% Phenylephrine hydrochloride 0,12% ophthalmic solution
- Where
- Argentina
- Volunteers
- 255 people
- Sponsor
- Laboratorios Poen
Cataract
Evaluate the Safety of DEXYCU for the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
- Trial name
- NCT05191706
- Testing
- Dexamethasone, Prednisolone Acetate Ophthalmic
- Where
- 9 sites in United States
- Volunteers
- 17 people
- Sponsor
- EyePoint Pharmaceuticals, Inc.
Inflammation
Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.
- Trial name
- NCT00429923
- Testing
- Difluprednate
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- Sirion Therapeutics, Inc.
Post-surgical Ocular Inflammation, Post-surgical Ocular Pain
Study to See How Well an Eye Drop, SURF-201, Works and What Side Effects There Are in Cataract Surgery Subjects
SURF-201 is being studied for the treatment of eye inflammation and pain in people who are undergoing cataract surgery. SURF-201 is an investigational drug (which means the study drug is currently being tested) in the form of a…
- Trial name
- NCT04324359
- Testing
- SURF-201
- Where
- 10 sites in United States
- Volunteers
- 91 people
- Sponsor
- Surface Ophthalmics, Inc.
Uveitis, Posterior, Uveitis, Intermediate
Safety and Effectiveness of Acthar Gel for Inflammation of the Eye's Uvea (Middle Layer)
The main reason for this study is to see if Acthar Gel can reduce inflammation in the uvea. Also, safety information when using it for this purpose will be collected.
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Trial name
- NCT03656692
- Testing
- Acthar Gel
- Where
- 8 sites in United States
- Volunteers
- 5 people
- Sponsor
- Mallinckrodt
Cataracts
Nepafenac 0.1% Eye Drops, Suspension Compared to Ketorolac Trometamol 0.5% Eye Drops, Solution and Placebo
To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain…
- Trial name
- NCT00405730
- Testing
- Nepafenac 1mg/ml eye drops, suspension, Ketorolac Trometamol 5 mg/ml eye drops, solution, Nepafenac vehicle eye drops
- Where
- France
- Volunteers
- 227 people
- Sponsor
- Alcon Research
Macular Edema Secondary to Inflammation
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
- Trial name
- PINNACLE (NCT06996080)
- Testing
- KSI-101
- Where
- 56 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Kodiak Sciences Inc
Dry Eye Disease (DED)
A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study
The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.
- Trial name
- NCT07234318
- Testing
- Cyclosporin
- Where
- Austria
- Volunteers
- 25 people
- Sponsor
- Laboratoires Thea
Post Surgical Ocular Inflammation and Pain
Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain
The primary objective of the study is to investigate the efficacy and safety of KPI-121 1.0% ophthalmic suspension compared to placebo in subjects who have undergone cataract surgery.
- Trial name
- NCT02793817
- Testing
- KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
- Where
- 35 sites in United States
- Volunteers
- 520 people
- Sponsor
- Kala Pharmaceuticals, Inc.